Last reviewed · How we verify
LMT
LMT is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to lower blood glucose.
LMT is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to lower blood glucose. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | LMT |
|---|---|
| Sponsor | Sanofi |
| Drug class | GLP-1 receptor agonist |
| Target | GLP-1R |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
LMT activates glucagon-like peptide-1 (GLP-1) receptors on pancreatic beta cells, stimulating glucose-dependent insulin secretion. It also suppresses glucagon secretion and slows gastric emptying, collectively reducing postprandial and fasting blood glucose levels. The long-acting formulation allows for less frequent dosing compared to shorter-acting GLP-1 agonists.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Gastrointestinal disorders
Key clinical trials
- Standardizing Swallow Pressure Measurements (NA)
- Further Lipid-Lowering With PCSK9 Inhibitors for Cardiovascular Outcomes in High-Risk Coronary Plaques Assessed by CT Angiography (NA)
- An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (PHASE3)
- Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia (PHASE2)
- Goal-Directed Resilience Training to Mitigate Chronic Pain in Former Football Players (NA)
- Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE) (PHASE3)
- Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE) (PHASE3)
- Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |